Multi-center, Randomized, Evaluator-blind, Active-controlled, Study to Determine the Safety, Tolerability, and Efficacy of Multiple Daily Doses of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infection

Trial Profile

Multi-center, Randomized, Evaluator-blind, Active-controlled, Study to Determine the Safety, Tolerability, and Efficacy of Multiple Daily Doses of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs LFF 571 (Primary) ; Vancomycin
  • Indications Clostridium infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2013 Planned end date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 15 Sep 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-000947-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top